The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
Open accessAbstract
Of 221 patients with breast cancer of known epidermal growth factor receptor (EGFR) and oestrogen receptor (ER) status, 99 had developed recurrences during the period of follow-up (range 3-60 months, median 24 months). Of these, 72 received endocrine therapy as first-line treatment for relapse. Immunohistochemical assessment of c-erbB-2 protein product expression was made using paraffin-embedded tumour tissue from 65 of these 72 patients. Including patients whose disease remained stable for more than 6 months with those showing an objective response (CR or PR for more than 3 months), only one (7%) of 14 c-erbB-2 positive tumours responded to endocrine manipulation compared with 19 (37%) of 51 c-erbB-2 negative tumours (P less than 0.05). Coexpression of c-erbB-2 reduced the response rate of ER positive patients from 48% to 20% and of ER negative cases from 27% to 0% (P less than 0.01). EGFR and c-erbB-2 protein appeared to have additive effects in reducing the likelihood of response, and none of eight patients with EGFR positive, c-erbB-2 positive tumours derived benefit from endocrine therapy. The results of this study suggest that c-erbB-2 protein overexpression, a marker of poor prognosis in breast cancer, is associated with a lack of response to endocrine therapy on relapse, and particularly in combination with EGFR may be useful in directing therapeutic choices.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richard, J., Sainsbury, C., Needham, G., Farndon, J., Malcolm, A., & Harris, A. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90593-9 · Cited by 892
Self-citationThe value of estrogen and progesterone receptors in the treatment of breast cancer
Osborne, C. K., Yochmowitz, M. G., Knight, W. A., & McGuire, W. L. (1980) · Cancer · doi:10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u · Cited by 720
Hayward, J. L., Carbone, P. P., Heuson, J.-C., Kumaoka, S., Segaloff, A., & Rubens, R. D. (1977) · Cancer · doi:10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f · Cited by 623
Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., & Horne, C. H. W. (1989) · PubMed · Cited by 582
Self-citationAdjuvant tamoxifen in the management of operable breast cancer : Scottish Trial
Scottish Cancer Trials Office (1987) · The Lancet · Cited by 428
CONTROLLED TRIAL OF TAMOXIFEN AS SINGLE ADJUVANT AGENT IN MANAGEMENT OF EARLY BREAST CANCER
(1985) · The Lancet · doi:10.1016/s0140-6736(85)92206-8 · Cited by 309
ADJUVANT TAMOXIFEN IN THE MANAGEMENT OF OPERABLE BREAST CANCER: THE SCOTTISH TRIAL
Breast Cancer Trials Committee (1987) · The Lancet · doi:10.1016/s0140-6736(87)90762-8 · Cited by 225
Nicholson, S., Halcrow, P., Farndon, J., Sainsbury, J. R. C., Chambers, P., & Harris, A. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91202-6 · Cited by 218
Self-citationExpression of the c‐erb B‐2 protein in normal and transformed cells
Gullick, W. J., Berger, M. S., Bennett, P. L. P., Rothbard, J. B., & Waterfield, M. D. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910400221 · Cited by 197
New storage procedure for human tumor biopsies prior to estrogen receptor measurement.
Crawford, D., COWAN, S. K., Hyder, S. M., McMenamin, M., Smith, D. A. B., & LEAKE, R. E. (1984) · PubMed · Cited by 46
Cited by
Prognostic Factors in Breast Cancer: College of American Pathologists Consensus Statement 1999
Fitzgibbons, P. L., Page, D. L., Weaver, D., Thor, A. D., Allred, D. C., Clark, G. M., Ruby, S. G., O'Malley, F., Simpson, J. F., Connolly, J. L., et al. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G., Robinson, R. A., Harris, C., El-Naggar, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2894 · Cited by 802
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
ERBB2 oncogene in human breast cancer and its clinical significance
Révillion, F., Bonneterre, J., & Peyrat, J. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10157-5 · Cited by 448
Metadata
- Authors
- Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C.
- Venue
- British Journal of Cancer
- Published
- 1992-01
- Volume
- 65
- Issue
- 1
- Pages
- 118-121
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1977221327
- Cited by
- 379
- References
- 10
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. https://app.cochat.ai/papers/10.1038/bjc.1992.22
- The paper
- Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992). Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. British Journal of Cancer. https://doi.org/10.1038/bjc.1992.22
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
